Creative Medical Technology Holdings, Inc. (CELZ) stock

CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30

$0.62−0.01 (-2.08%)

Close on Nov 12, 2026Market cap $4.06MP/E –Yield –

Creative Medical Technology ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Creative Medical Technology's ebitda for the twelve months ending Mar 31, 2025 was -$6.23M. For fiscal 2024 it was -$5.69M.

Period	Period end	Value	Change
FY2024	Dec 31, 2024	-$5.69M	–
FY2023	Dec 31, 2023	-$5.56M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q1 FY2025	Mar 31, 2025	-$1.61M	–
Q4 FY2024	Dec 31, 2024	-$1.88M	–
Q3 FY2024	Sep 30, 2024	-$1.11M	–
Q2 FY2024	Jun 30, 2024	-$1.63M	–
Q1 FY2024	Mar 31, 2024	-$1.08M	–
Q3 FY2022	Sep 30, 2022	-$1.02M	–

Parsed from the XBRL in Creative Medical Technology's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jun 12, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CELZ.

Advertisement
300 × 250

See a number that looks wrong?